keyword
MENU ▼
Read by QxMD icon Read
search

Lymphocytic leukemia

keyword
https://www.readbyqxmd.com/read/29656333/interferon-%C3%AE-salvage-treatment-is-effective-for-patients-with-acute-leukemia-myelodysplastic-syndrome-with-unsatisfactory-response-to-minimal-residual-disease-directed-donor-lymphocyte-infusion-after-allogeneic-hematopoietic-stem-cell-transplantation
#1
Xiaodong Mo, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang
The efficacy of salvage interferon-α (IFN-α) treatment was investigated in patients with unsatisfactory response to minimal residual disease (MRD)-directed donor lymphocyte infusion (DLI) (n = 24). Patients who did not become MRD-negative at 1 month after DLI were those with unsatisfactory response and were eligible to receive salvage IFN-α treatment within 3 months of DLI. Recombinant human IFN-α-2b injections were subcutaneously administered 2-3 times a week for 6 months. Nine (37.5%), 6 (25.0%), and 3 (12...
April 14, 2018: Frontiers of Medicine
https://www.readbyqxmd.com/read/29655704/a-library-of-phosphoproteomic-and-chromatin-signatures-for-characterizing-cellular-responses-to-drug-perturbations
#2
Lev Litichevskiy, Ryan Peckner, Jennifer G Abelin, Jacob K Asiedu, Amanda L Creech, John F Davis, Desiree Davison, Caitlin M Dunning, Jarrett D Egertson, Shawn Egri, Joshua Gould, Tak Ko, Sarah A Johnson, David L Lahr, Daniel Lam, Zihan Liu, Nicholas J Lyons, Xiaodong Lu, Brendan X MacLean, Alison E Mungenast, Adam Officer, Ted E Natoli, Malvina Papanastasiou, Jinal Patel, Vagisha Sharma, Courtney Toder, Andrew A Tubelli, Jennie Z Young, Steven A Carr, Todd R Golub, Aravind Subramanian, Michael J MacCoss, Li-Huei Tsai, Jacob D Jaffe
Although the value of proteomics has been demonstrated, cost and scale are typically prohibitive, and gene expression profiling remains dominant for characterizing cellular responses to perturbations. However, high-throughput sentinel assays provide an opportunity for proteomics to contribute at a meaningful scale. We present a systematic library resource (90 drugs × 6 cell lines) of proteomic signatures that measure changes in the reduced-representation phosphoproteome (P100) and changes in epigenetic marks on histones (GCP)...
April 10, 2018: Cell Systems
https://www.readbyqxmd.com/read/29651698/mitogenic-activity-of-artocarpus-lingnanensis-lectin-and-its-apoptosis-induction-in-jurkat-t-cells
#3
Linjie Zeng, Lu Li, Qiyan Zeng, Yong Deng, Lijun Yin, Liejun Liao
Lectins are a class of carbohydrate-binding proteins or glycoproteins and used in the purification and characterization of glycoproteins according to their specificity to carbohydrates. In the present study, the mitogenic activity of Artocarpus lingnanensis lectin (ALL) and its apoptosis induction in Jurkat T cells were explored. MTT assay revealed strong mitogenic potential of ALL. Meanwhile, the anti-cancer activity of ALL was also explored using the human leukemic Jurkat T cell line. ALL exhibited strong binding affinity (97%) to the cell membrane, which could be effectively inhibited by N-acetyl-D-galactosaminide (NAD)...
April 12, 2018: Journal of Natural Medicines
https://www.readbyqxmd.com/read/29651369/unusual-relapse-of-chronic-lymphocytic-leukemia-after-remission
#4
Wajeeha Rizvi, Quoc Truong
Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia with over 20,000 estimated cases in 2017. Leukemic involvement of the nervous system from CLL causing neurologic symptoms is reported in only about one percent of patients. Unfortunately, there is no current standard therapy for the treatment of CLL leptomeningeal disease. In this case, we discuss an unusual presentation of CLL leptomeningeal disease misdiagnosed as chronic rebound headache. A 61-year-old female was diagnosed with Rai stage I CLL in 2002...
February 9, 2018: Curēus
https://www.readbyqxmd.com/read/29651349/-listeria-monocytogenes-infection-in-hairy-cell-leukemia-a-case-report-and-literature-review
#5
James C Barton, Hayward S Edmunds
Listeria monocytogenes infections have been described in patients with diverse types of malignancy, especially leukemia. We report the case of a 65-year-old man with previously untreated hairy cell leukemia characterized by CD5 positivity and trisomy 12 (3% of blood lymphocytes) who developed bacteremia due to L. monocytogenes serotype 1/2b. We summarize clinical features and treatment of this patient and five previously reported patients with hairy cell leukemia who also had L. monocytogenes infections. All six patients were men...
2018: Case Reports in Hematology
https://www.readbyqxmd.com/read/29650518/secretory-igm-exacerbates-tumor-progression-by-inducing-accumulations-of-mdscs-in-mice
#6
Chih-Hang Anthony Tang, Shiun Chang, Ayumi Hashimoto, Yi-Ju Chen, Chang Won Kang, Anthony R Mato, Juan R Del Valle, Dmitry Gabrilovich, Chih-Chi Andrew Hu
Chronic lymphocytic leukemia cells can secrete immunoglobulin M. However, it is not clear whether secretory IgM (sIgM) plays a role in disease progression. We crossed the Eμ-TCL1 mouse model of CLL, in which the expression of human TCL1 oncogene was driven by the V(H) promoter-Ig(H)-Eμ enhancer, with MD4 mice whose B cells produced B cell receptor (membrane-bound IgM) and sIgM with specificity for hen egg lysozyme (HEL). CLL cells developed in these MD4/Eμ-TCL1 mice reactivated a parental Ig gene allele and secreted IgM, and did not recognize HEL...
April 12, 2018: Cancer Immunology Research
https://www.readbyqxmd.com/read/29649904/economic-burden-of-treatment-failure-in-chronic-lymphocytic-leukemia-patients
#7
Song Wang, Marie-Hélène Lafeuille, Patrick Lefebvre, Hela Romdhani, Bruno Emond, Mekré Senbetta
OBJECTIVE: This study assessed healthcare costs of first-line treatment failure (TF) in patients with chronic lymphocytic leukemia (CLL), a subtype of non-Hodgkin's lymphoma. METHODS: Pre-diagnosis treatment-naïve adults with ≥2 CLL diagnoses initiated on an antineoplastic agent (index date) after their first CLL diagnosis with ≥12 and ≥6 months of continuous observation pre- and post-index, respectively, were selected from the Truven Health MarketScan® Research Databases...
April 12, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29649617/reversal-of-t-cell-exhaustion-by-the-first-donor-lymphocyte-infusion-is-associated-with-the-persistently-effective-anti-leukemic-responses-in-patients-with-relapsed-aml-after-allo-hsct
#8
Long Liu, Ying-Jun Chang, Lan-Ping Xu, Xiao-Hui Zhang, Yu Wang, Kai-Yan Liu, Xiao-Jun Huang
Donor lymphocyte infusion is an effective approach to treat acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) that significantly improves the survival of relapsed patients. However, the mechanism of an effective anti-leukemic response following DLI in AML relapse remains elusive. Here, we investigated the role of T cell exhaustion in AML relapse after allo-HSCT in prospective cohorts of 41 patients with the first AML relapse and 41 non-relapsed AML controls after allo-HSCT and determined whether DLI exerts effective anti-leukemic effects by reversing T cell exhaustion in the relapsed cohorts by detecting the phenotypes and functions of T cells using flow cytometry...
April 9, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29649100/targeting-the-adenosinergic-axis-in-chronic-lymphocytic-leukemia-a-way-to-disrupt-the-tumor-niche
#9
REVIEW
Tiziana Vaisitti, Francesca Arruga, Silvia Deaglio
Targeting adenosine triphosphate (ATP) metabolism and adenosinergic signaling in cancer is gaining momentum, as increasing evidence is showing their relevance in tumor immunology and biology. Chronic lymphocytic leukemia (CLL) results from the expansion of a population of mature B cells that progressively occupies the bone marrow (BM), the blood, and peripheral lymphoid organs. Notwithstanding significant progress in the treatment of these patients, the cure remains an unmet clinical need, suggesting that novel drugs or drug combinations are needed...
April 12, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29644615/assessment-of-the-inhalation-risks-associated-with-working-in-printing-rooms-a-study-on-the-staff-of-eight-printing-rooms-in-beijing-china
#10
Mingxing Su, Rubao Sun, Xun Zhang, Shen Wang, Ping Zhang, Zhengquan Yuan, Chao Liu, Qiang Wang
The concentration of pollution directly determines the occupational health risk, and the exposure time is an important influencing factor. We evaluated the inhalation risks of working in a printing room. Eight units with centralized printing rooms were randomly selected. Formaldehyde, ozone, benzene, toluene, xylene, and fine particulate matter were detected by spectrophotometry, gas chromatography, and direct reading instruments, respectively. The U.S. EPA inhalation risk assessment model was used to assess cancer and non-cancer risks...
April 11, 2018: Environmental Science and Pollution Research International
https://www.readbyqxmd.com/read/29628774/management-of-relapsed-refractory-marginal-zone-lymphoma-focus-on-ibrutinib
#11
REVIEW
Nathan M Denlinger, Narendranath Epperla, Basem M William
Marginal zone lymphomas (MZLs) consist of a diverse family of malignancies, which are derived from B-cells. The disease subtypes are recognized extranodal, nodal, and splenic MZLs. The disease characteristics, clinical course, and treatment vary considerably based on the site of involvement. In 2017, the US Food and Drug Administration approved ibrutinib, a first in class Bruton's tyrosine kinase inhibitor that revolutionized the care of chronic lymphocytic leukemia patients; for, the treatment of relapsed/refractory MZL based on pivotal open-label Phase II trial demonstrated an overall response rate of 48%, with a complete response rate of 3%, median progression-free survival of 14...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29618685/-splenic-diffuse-red-pulp-small-b-cell-lymphoma-diagnosed-by-splenectomy-initially-mimicking-hairy-cell-leukemia-japanese-variant
#12
Yukika Yamada, Miyoko Miura, Mayu Tagari, Kazuo Oshimi, Tomokazu Shiragata, Wataru Suga, Tatsurou Takahashi, Kazuyoshi Shimizu, Kouichi Ohshima, Keizou Kajiwara
A 62-year-old man presented to the hospital with thrombocytopenia, and splenomegaly was detected. His blood films prepared by natural air drying revealed medium-sized lymphocytes with unevenly distributed large and small villous projections. The cytoplasm was basophilic, nuclei were oval with clumped chromatin, and nucleoli were absent in most cells. Immune phenotypes CD19+, CD20+, CD11c+, FMC7+, IgM+, and Igκ+ were detected. TRAP stain appeared negative, IgH JH chain genes were monoclonally rearranged, and BRAF V600E mutation was not detected...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/29616870/the-influence-of-lymphoid-reconstitution-kinetics-on-clinical-outcomes-in-allogeneic-stem-cell-transplantation
#13
David J Kobulnicky, Roy T Sabo, Shashank Sharma, Ali S Shubar Ali, Kristen M Kobulnicky, Catherine H Roberts, William B Clark, Harold M Chung, John M McCarty, Amir A Toor
Lymphoid recovery following myeloablative stem cell transplantation (SCT) displays a logistic pattern of exponential growth followed by a plateau. Within this logistic framework, lymphoid recovery is characterized by the parameters R (slope of ascent), a (time of maximal rate of ascent) and K (plateau), the 'steady-state' lymphocyte count. A retrospective analysis of allogeneic SCT performed from 2008 to 2013 was undertaken to compare lymphoid recovery and clinical outcomes in 131 patients with acute myelogenous leukemia, acute lymphocytic leukemia, and myelodysplastic syndromes...
April 4, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29616852/rituximab-addition-to-chemotherapy-in-real-world-patients-with-chronic-lymphocytic-leukemia-effective-in-first-line-but-indication-of-lack-of-efficacy-in-subsequent-lines-of-therapy
#14
Lina van der Straten, Avinash G Dinmohamed, Peter E Westerweel, Anton W Langerak, Jurgen Riedl, Jeanette K Doorduijn, Arnon P Kater, Mark-David Levin
No abstract text is available yet for this article.
April 4, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29610115/a-phase-1-study-of-lenalidomide-and-ibrutinib-in-combination-with-rituximab-in-relapsed-and-refractory-cll
#15
Chaitra Ujjani, Hongkun Wang, Alan Skarbnik, Neel Trivedi, Pari Ramzi, Nadia Khan, Bruce D Cheson
Attempts to improve upon the activity of ibrutinib in chronic lymphocytic leukemia (CLL) include the addition of targeted therapies. The combination of lenalidomide and rituximab demonstrated an overall response rate (ORR) of 66% with a complete response (CR) of 12% in the relapsed/refractory setting. Based on these data, we conducted a phase 1 study of rituximab (R), lenalidomide (L), and ibrutinib (I) in relapsed/refractory CLL. Patients received R 375 mg/m2 cycles 1 to 6 day 1, L on cycles 1 to 12 days 1 to 21, and I until disease progression...
April 10, 2018: Blood Advances
https://www.readbyqxmd.com/read/29608741/critically-elevated-potassium-in-a-55-year-old-female-with-chronic-lymphocytic-leukemia
#16
Jing Cao, Amy B Karger
Hyperkalemia in specimens from patients with chronic lymphocytic leukemia (CLL) may be due to tumor lysis syndrome (TLS) or specimen processing. This report describes a 55-year-old Caucasian woman with CLL who presented to an outside hospital with hyperkalemia and was transferred to a second hospital. Initial evaluation on the core laboratory chemistry analyzer (the VITROS 5600) and the ABL90 FLEX blood gas analyzer showed markedly elevated levels of potassium (K+). TLS was subsequently diagnosed, and dialysis was initiated...
March 28, 2018: Laboratory Medicine
https://www.readbyqxmd.com/read/29607828/t-cell-large-granular-lymphocytic-leukemia-with-pulmonary-hypertension
#17
Sidra Khalid, Hamed Daw, Miriam Jacob, Megan Nakashima
T cell large granular lymphocytic leukemia is a hematological disorder which is characterized by the proliferation of CD 3+ cytotoxic T cells. We present a case about a patient who was diagnosed with T cell large granular lymphocytic leukemia and then developed pulmonary hypertension. He was treated for his leukemia with methotrexate and simultaneously treated for his pulmonary hypertension with selexipag and ambrisentan. As his leukemia improved, we also noticed an improvement in his pulmonary hypertension from a NYHA class IV to class I...
January 2018: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/29603337/cxcr4-blockade-improves-leukemia-eradication-by-allogeneic-lymphocyte-infusion
#18
Chun-Hui Jin, Yang Li, Jinxing Xia, Yuying Li, Mo Chen, Zheng Hu, Markus Y Mapara, Wei Li, Yong-Guang Yang
Persistent low levels of disease in bone marrow, an immunoprivileged tissue, are responsible for relapse following allogeneic hematopoietic cell transplantation. Using mouse models carrying primary human acute lymphoblast leukemia derived from MLL-AF9-overexpressing human hematopoietic stem cells, we demonstrate that allogeneic lymphocyte infusion (ALI)-mediated graft-vs.-leukemia effects selectively spare leukemia cells in the bone marrow. The resistance of leukemia cells to ALI within bone marrow is due to the immunosuppressive status of the tissue, as ALI achieved a significantly increased complete remission rate when leukemia cells were dislodged from bone marrow by treatment with a CXCR4 antagonist AMD3100...
March 30, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29599682/paraneoplastic-pemphigus-with-anti-desmocollin-3-autoantibodies-and-chronic-lymphocytic-leukemia
#19
Alicja Adaszewska, Norito Ishii, Jadwiga Dwilewicz-Trojaczek, Katarzyna Woźniak, Takashi Hashimoto, Cezary Kowalewski
No abstract text is available yet for this article.
February 2018: Postȩpy Dermatologii i Alergologii
https://www.readbyqxmd.com/read/29595064/accelerating-drug-development-in-pediatric-cancer-a-novel-phase-i-study-design-of-venetoclax-in-relapsed-refractory-malignancies
#20
Andrew E Place, Kelly Goldsmith, Jean-Pierre Bourquin, Mignon L Loh, Lia Gore, Daniel A Morgenstern, Yeshwant Sanzgiri, David Hoffman, Ying Zhou, Jeremy A Ross, Betty Prine, Mohamad Shebley, Megan McNamee, Thalia Farazi, Su Young Kim, Maria Verdugo, Leanne Lash-Fleming, C Michel Zwaan, Josef Vormoor
Venetoclax is a highly selective, potent BCL-2 inhibitor that is approved for some patients previously treated for chronic lymphocytic leukemia, and has shown promising activity in adult studies across several hematologic malignancies. Preclinical studies have demonstrated venetoclax activity in pediatric patient-derived xenograft models and cell lines; however, clinical studies in pediatric patients have yet to be conducted. The prognosis is poor for children with most relapsed/refractory malignancies, and limited treatment options result in unmet clinical need...
March 29, 2018: Future Oncology
keyword
keyword
20449
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"